Søren Rasmussen

Title: **Søren Rasmussen: Innovator in GPCR Structural Biology**

Introduction

Søren Rasmussen, a notable inventor based in Frederiksberg, Denmark, has made significant contributions to the field of structural biology and pharmacology. His innovative work centers around G protein coupled receptors (GPCRs), which play critical roles in cell signaling and are key targets in drug discovery. With one patent to his name, Rasmussen's research holds promise for advancing therapeutic strategies in various diseases.

Latest Patents

Rasmussen's sole patent, titled "Binding domains directed against GPCR:G protein complexes and uses derived thereof," addresses the structural biology of GPCRs and their signaling pathways. The invention primarily relates to binding domains designed to specifically interact with GPCR:G protein complexes. This patent also encompasses nucleic acid sequences that encode these binding domains and the cells capable of expressing them. These innovative binding domains serve as universal tools for characterizing the dynamics of GPCR interactions with downstream G proteins and various ligands. Moreover, they provide valuable resources for drug screening and discovery that exploit GPCR:G protein complexes.

Career Highlights

Throughout his career, Søren Rasmussen has been associated with prominent research institutions such as Vrije Universiteit Brussel and VIB (Vlaamse Instelling voor Biotechnologie). His academic and research engagements have equipped him with the necessary expertise in the burgeoning area of GPCR research, facilitating insightful discoveries that bridge the gap between basic research and therapeutic application.

Collaborations

Rasmussen has had the opportunity to collaborate with esteemed colleagues, including Jan Steyaert and Els Pardon. These partnerships have fostered a dynamic research environment, leading to interdisciplinary conversations that enhance the research output and innovation within the field of GPCR biology.

Conclusion

Søren Rasmussen's innovative contributions to GPCR structural biology and signaling illustrate the profound impact that targeted research can have on understanding complex biological systems. His patent highlights the potential of binding domains as versatile tools for advancing drug discovery endeavors. As we continue to explore the intricacies of GPCRs, inventors like Rasmussen pave the way for exciting developments in therapeutic interventions.